2-Pyridyloxy-3-Ester-4-Nitrile Orexin Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders related to orexin receptor activity lack effective antagonists, which are necessary for managing sleep disorders, insomnia, and other related conditions.
Innovation Solution
Development of 2-pyridyloxy-3-ester-4-nitrile compounds that act as antagonists for orexin receptors, specifically targeting OX1R and OX2R, to inhibit orexin receptor activity and treat associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurological and psychiatric disorders are used, then existing therapeutic options are available, but effective orexin receptor antagonists are lacking
Solution Approach 1:
The patent employs parameter changes by systematically varying chemical structures of the compounds (different substituents R1-R6, core structures A-B-C-D) to optimize orexin receptor antagonism. This includes modifying molecular weight, lipophilicity, and structural features to achieve desired pharmacological properties while maintaining effectiveness against OX1R and OX2R
Solution Approach 2:
The invention creates composite molecular structures combining multiple functional groups (pyridine rings, ester groups, nitrile groups, aromatic substituents) to develop compounds with enhanced orexin receptor binding affinity and selectivity, resulting in more effective therapeutic agents
2Adaptability or versatility
If orexin receptor antagonists are developed, then sleep disorders and related conditions can be treated, but lack of such compounds currently limits therapeutic options
Solution Approach 1:
The patent segments the orexin receptor antagonism function into distinct compound classes with specific structural features (Formula I compounds, substituted pyridines, specific core structures) that can be independently optimized for different therapeutic indications including sleep disorders, eating disorders, and psychiatric conditions
Solution Approach 2:
The developed compounds are designed with universal applicability across multiple neurological and psychiatric disorders by targeting both OX1R and OX2R receptors, allowing a single compound class to address diverse conditions such as insomnia, narcolepsy, obesity, and anxiety disorders
Data Source
AI summary
The present invention is directed to 2-pyridyloxy-3-ester-4-nitrile compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-3-ester-4-nitrile compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.